ArticleJournal of leukocyte biology2025
The macrocyclic peptide rhesus theta defensin 1 activates interferon and antiviral pathways in human monocytes.
Article in Journal of leukocyte biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Rhesus theta defensin (RTD)-1, a cyclic antimicrobial peptide, regulates gene expression and immune signaling pathways in cell culture and animal models of immune-mediated diseases. In lipopolysaccharide-stimulated cells, RTD-1 inhibition of proinflammatory cytokine secretion and gene expression is mediated through inhibition of the NF-κB and MAP kinase signaling pathways. To gain insights into RTD-1 regulation of naïve cells, we performed RNA sequencing (RNA-seq) to determine the effect of the peptide on global gene expression in human monocytes and THP-1 monocytes. In both cell types, analysis of differentially expressed genes revealed stimulation of interferon and antiviral gene expression pathways. RTD-1 induced Y701 phosphorylation of STAT1 and activated the ISRE reporter in a JAK-dependent manner. Stimulation of the ISRE reporter by RTD-1 was interferon-α/β receptor dependent but was independent of its NF-κB inhibitory activity in lipopolysaccharide-stimulated cells. RTD-1 inhibited infection of vesicular stomatitis virus pseudotyped with G glycoprotein or SARS-CoV-2 spike protein in THP-1 and Vero E6 cells, respectively. RTD-1 also inhibited infection of Calu-3 2B4 cells by SARS-CoV-2 virus, demonstrating antiviral activity of RTD-1 in diverse cell types. These results demonstrate that RTD-1 stimulates interferon and antiviral pathways, potentially priming cells for resistance to viral infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.